Abstract
Liquiritin is a flavonoid glycoside extracted from traditional Chinese medicine, Radix et Rhizoma Glycyrrhizae. The provide evidence has found that liquiritin has been found to be beneficial to cardiovascular disease. Inflammation and oxidation play key roles in cardiovascular diseases. In this review, the natural sources, biosynthesis, pharmacology and molecular docking of liquiritin were reviewed for the first time. Additionally, we have highlighted the target prediction of liquiritin. Docking results displayed that the three targets with the largest difference in VINA scores were TLR4, Keap-1 and AMPK, which suggested that liquiritin was likely to act on TLR4, Keap-1 and AMPK. Liquiritin will provide theoretical basis for future development and research in cardiovascular diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
